Furthermore, combination treatments of PLK4 inhibitors with other therapeutic agents in breast and other cancers might be of value, especially to augment tumor responses to immunotherapy in patients with metastatic breast cancer, an approach that is already being implemented in clinical trials (Table 3). The gene discussed is PLK4; the disease is neoplasm.